Compare Amphastar Pharmaceuticals Inc (AMPH) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs JD.Com Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while JD.Com Inc trades at $28.83 (market cap $38.39B). The key difference: JD.Com Inc is far larger — about 46.5× Amphastar Pharmaceuticals Inc's market cap, and JD.Com Inc pays a 3.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | JD | |
|---|---|---|
Market Cap | $826.08M | $38.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $36.17 |
52-Week Low | $16.87 | $25.19 |
Enterprise Value | $1.22B | $24.55B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
JD.com trades at $28.20, up 1.66% today, with a bullish technical signal from moving averages. The company reported revenue of $1.31 trillion in 2025, though net income fell to $19.63 billion, reducing the profit margin to 1.49%. Recent quarters show consistent earnings beats, and analyst sentiment is strongly positive with a consensus price target of $39.20. News highlights include a rally in Chinese tech stocks and ongoing legal investigations.
The outlook is supported by low valuation multiples and strong cash flow, but risks include regulatory scrutiny and margin pressure. Upside potential exists if earnings growth resumes, yet investor caution is warranted due to legal overhangs and competitive dynamics in e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
